Repligen Salute del bilancio
Criteri Salute finanziaria verificati 5/6
Repligen ha un patrimonio netto totale di $2.1B e un debito totale di $551.0M, che porta il suo rapporto debito/patrimonio netto a 26.1%. Le sue attività totali e le sue passività totali sono rispettivamente $3.0B e $838.1M. L'EBIT di Repligen è $65.3M rendendo il suo rapporto di copertura degli interessi -24.9. Ha liquidità e investimenti a breve termine pari a $810.4M.
Informazioni chiave
26.09%
Rapporto debito/patrimonio netto
US$551.05m
Debito
| Indice di copertura degli interessi | -24.9x |
| Contanti | US$810.45m |
| Patrimonio netto | US$2.11b |
| Totale passività | US$838.15m |
| Totale attività | US$2.95b |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
Aggiornamento narrativa • Sep 04
RGEN: Cancer Vaccine Exposure And Bioprocess Deals Will Shape Outlook
Analysts have nudged their price expectations for Repligen modestly higher, with the fair value estimate moving from about $182.05 to $187.70. This shift reflects updated views on its exposure to Moderna's cancer vaccine program, recent price target increases from several firms, and revised assumptions for revenue growth and profitability.
Aggiornamento narrativa • Aug 20
RGEN: Cancer Vaccine Hype And BioLife Deal Will Test Overstretched Expectations
Analysts have raised the implied fair value for Repligen to about $145.92 from $142, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that are supported by recent research highlighting exposure to Moderna's cancer vaccine work, a series of higher external price targets, and a constructive view on bioprocessing demand. Analyst Commentary Recent Street research around Repligen gives you a mix of enthusiasm around new modalities and bioprocessing demand, along with some caution on valuation, sector sentiment, and execution risks.Aggiornamento narrativa • Jul 29
RGEN: Cell Therapy Deal And Gene Therapy Lap Will Drive Upside
Analysts have nudged their fair value estimate for Repligen higher to about $182 from roughly $176, citing stronger expectations for revenue growth and sector valuations, supported by recent price target increases and rating upgrades across the Street. Analyst Commentary Recent Street research on Repligen gives you a mix of optimism about long term growth drivers and caution about sector sentiment, which helps explain the modest lift in fair value estimates.Aggiornamento narrativa • Jun 27
RGEN: Bioprocess Recovery And Clean Gene Therapy Lap Will Drive Future Upside
Analysts reduced the fair value estimate for Repligen to $176.11 from $183.88 and lowered the implied future P/E assumption to about 80x from roughly 100x, citing sector wide price target cuts, even as some research points to early signs of recovery in bioprocessing and confidence in the company's balance sheet and product positioning. Analyst Commentary Street research on Repligen highlights a mix of optimism about the bioprocessing recovery and caution around valuation and sector sentiment.Aggiornamento narrativa • Jun 13
RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance
Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.Seeking Alpha • May 31
Repligen Has A Cleaner Recovery Angle, But With High Valuation
Summary Repligen is recovering after a difficult 2024, with Q1 2026 revenue up 15% and 11% organic. Polymem, China, PAT, and the Transformation Office make the story cleaner, but execution still matters. I like Repligen's balance sheet, as it has plenty of liquidity with good cash flows to continue funding M&A deals or potential growth in Asia. Unfortunately, my main issue with RGEN is its expensive valuation, which leaves little margin of safety for investors at these levels. Read the full article on Seeking AlphaAggiornamento narrativa • May 30
RGEN: Firmer Bioprocess Backdrop And Hubs Expansion Will Shape Long Term Outlook
Repligen's updated analyst price target of $142 reflects a largely unchanged fair value. Analysts point to a mix of reduced P/E assumptions and slightly stronger expectations for revenue growth and profitability, supported by recent research that highlights a firmer bioprocess backdrop and diversified growth drivers.Aggiornamento narrativa • May 11
RGEN: Recalibrated Street Expectations And Hubs Expansion Will Shape Long Term Outlook
Analysts now place Repligen's fair value at $142, a $2 adjustment that reflects a mix of recent price target cuts and increases as they weigh updated growth expectations, margins, and P/E assumptions from the latest round of Street research. Analyst Commentary The latest Street research on Repligen shows a split tape, with some firms lifting targets and others cutting them, which nets out to the modest US$2 bump in the aggregated fair value estimate to US$142.Aggiornamento narrativa • Apr 25
RGEN: recalibrated Street Expectations Will Shape Bullish Long Term Outlook
The analyst price target for Repligen has been reduced from about $160.90 to $140.00, as analysts factor in updated assumptions for revenue growth, profit margins, discount rates and future P/E following a mix of recent target cuts and one upward revision across the Street. Analyst Commentary Street research on Repligen over recent months points to a mixed but generally more cautious stance, with several firms trimming price targets while one research house lifted its target.Aggiornamento narrativa • Apr 09
RGEN: Multi Year Guidance And M&A Dry Powder Will Support Future Upside
Narrative Update on Repligen The analyst price target for Repligen has been adjusted slightly lower, with the updated fair value moving from about $186.82 to $183.88 as analysts factor in recent target cuts, alongside generally positive views on guidance and execution. Analyst Commentary Recent Street research on Repligen clusters around a group of target cuts following the latest Q4 report and FY26 outlook, alongside a smaller number of target increases.Aggiornamento narrativa • Mar 25
RGEN: Multi Year Guidance And M&A Focus Will Support Future Upside
Repligen's analyst price target has been adjusted modestly higher to $186.82, with analysts pointing to refreshed assumptions around revenue growth, profit margins, and future P/E expectations following recent target changes across firms such as H.C. Wainwright, UBS, Evercore ISI, Wells Fargo, and Barclays. Analyst Commentary Recent target changes reflect a mix of optimism and caution around Repligen, with analysts adjusting their models after the latest Q4 results and FY26 guidance.Aggiornamento narrativa • Mar 10
RGEN: M&A And New Bioprocessing Resins Will Support Future Upside
Narrative Update: Repligen Repligen's updated analyst price target reflects a modest reset, with fair value moving from about $190.89 to $186.28 as analysts factor in slightly lower revenue growth and profit margin assumptions along with a marginally higher discount rate, while still generally highlighting solid recent execution and cautious company guidance. Analyst Commentary Recent Street research on Repligen shows a mixed but generally constructive stance, with several firms trimming price targets while maintaining positive ratings.Aggiornamento narrativa • Feb 24
RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside
Analysts have raised their Repligen price target by $10 to $190.89, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$190.89 price target as better aligned with updated assumptions for discount rates and future P/E, suggesting the shares may not fully reflect their revised valuation framework.Aggiornamento narrativa • Feb 09
RGEN: M&A Ambitions And New Resins Portfolio Will Shape Bullish Outlook
Analysts have lifted their price target on Repligen by US$10, citing updated assumptions that reflect revised fair value estimates, a tweaked discount rate, adjusted revenue growth and profit margin expectations, and an updated future P/E multiple. Analyst Commentary Even with the higher price target, some research commentary points to risks that readers should keep in mind when weighing Repligen at current levels.Aggiornamento narrativa • Jan 26
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Further Upside
Analysts have nudged their price targets on Repligen higher, with our updated fair value estimate moving modestly to about US$190.89 per share. This is supported by recent Street research citing raised targets following a 3Q25 revenue beat and a relatively improving biopharma outlook, with growth across all franchises led by Process Analytics.Aggiornamento narrativa • Jan 12
RGEN: Process Analytics Strength And Biopharma Recovery Will Support Upside In 2025
Analysts have lifted their price target on Repligen to about US$190 from US$187, pointing to recent target raises, including Canaccord's move to US$165 on 3Q25 revenue outperformance, a relatively improving biopharma outlook, and solid contributions from Process Analytics and other franchises. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a higher price target as a reflection of stronger than expected 3Q25 revenue, which they view as supportive of the current valuation range.Aggiornamento narrativa • Dec 27
RGEN: Process Analytics Momentum And Biopharma Recovery Will Shape Risk Balanced Outlook
Narrative Update We are raising our Repligen fair value estimate from $131.29 to $160.36 per share as analysts lift price targets toward $160 to $165 on better than expected Q3 results, broad-based revenue growth led by Process Analytics, and an improving outlook for biopharma end markets. Analyst Commentary Recent Street research reflects a cautiously constructive stance on Repligen, with higher price targets acknowledging near term execution outperformance while still embedding meaningful risk around sustainability of growth.
Aggiornamento narrativa • Dec 13
RGEN: Bioprocessing Recovery And Guidance Raise Will Support Upside Potential
Analysts have nudged our Repligen price target higher to $165, reflecting a modest trim to fair value estimates to about $216.62 per share, alongside slightly lower long term revenue growth and discount rate assumptions, but reinforced by recent target increases from the Street on better than expected quarterly results, improving biopharma demand, and confidence in the company s bioprocessing driven double digit growth potential. Analyst Commentary Bullish analysts have become incrementally more constructive on Repligen following its recent quarterly performance, citing a healthier biopharma demand backdrop and stronger than expected execution across key franchises.Aggiornamento narrativa • Nov 27
RGEN: Volume Recovery and End-Market Stability Will Support Measured Upside in 2025
Narrative Update on Repligen Analysts have raised their price targets on Repligen by up to $15. They cite stronger-than-expected quarterly results and improved industry outlooks as driving positive momentum for the company.Articolo di analisi • Nov 12
Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point
Even though Repligen Corporation ( NASDAQ:RGEN ) posted strong earnings, investors appeared to be underwhelmed. We did...Aggiornamento narrativa • Nov 11
RGEN: End-Market Improvements Will Drive Stronger Momentum Through 2025
Analysts have increased their price target for Repligen slightly, from $184.76 to $187.00. They cite a recent revenue beat, an improving sector outlook, and expectations for continued growth across key business areas.Articolo di analisi • Oct 31
Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
Repligen Corporation ( NASDAQ:RGEN ) investors will be delighted, with the company turning in some strong numbers with...Aggiornamento narrativa • Oct 28
Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum
Repligen's analyst price target has been increased from $179.78 to $184.76, as analysts see improving market stability and anticipate a return to stronger revenue growth despite recent headwinds. Analyst Commentary Recent updates from street research highlight a renewed sense of optimism among analysts, along with acknowledgment of ongoing industry challenges.Articolo di analisi • Oct 04
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge
Repligen Corporation ( NASDAQ:RGEN ) shares have had a really impressive month, gaining 28% after a shaky period...Nuova narrativa • May 26
Biomanufacturing Expansion Will Create New Global Opportunities
Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.Seeking Alpha • Mar 20
Repligen: Ongoing Bioprocessing Market Recovery
Summary I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings. Despite challenges in the protein business, I expect 12% organic revenue growth in FY25, supported by new product launches and market normalization. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Summary Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. Also, I believe international revenue exposure and foreign exchange volatility present additional risks for RGEN’s near-term financial performance. Despite a healthy underlying business, RGEN faces valuation concerns, tax loss harvesting, and uncertain growth, leading to a "Hold" rating ahead of its earnings report. Read the full article on Seeking AlphaAnalisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $1.2B ) di RGEN superano le sue passività a breve termine ( $132.7M ).
Passività a lungo termine: Le attività a breve termine di RGEN ( $1.2B ) superano le sue passività a lungo termine ( $705.5M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: RGEN ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di RGEN è aumentato da 15.6% a 26.1% negli ultimi 5 anni.
Copertura del debito: Il debito di RGEN è ben coperto dal flusso di cassa operativo ( 24.5% ).
Copertura degli interessi: RGEN matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.
Bilancio
Scoprire le aziende sane
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/13 09:19 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Repligen Corporation è coperta da 31 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Luke Sergott | Barclays |
| Hugo Solvet | BNP Paribas |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |